Top Markets
Coin of the day
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
Rank in Stocks #16324
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with NestlΓ© Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in PΓ©rigny, France.
Share Price
$0.94180721
Market Cap
$22.26M
Change (1 day)
0.38%
Change (1 year)
-14.35%
Country
FR
Trade Valbiotis SA (ALVAL)

Category

EPS for Valbiotis SA (ALVAL)
EPS as of December 2025 TTM: $-0.57
According to Valbiotis SA latest financial reports and stock price the company's current EPS (TTM) is $-0.57. At the end of 2023 the company had a EPS of $-0.65 a decrease compared to its 2022 EPS that were of $-1.31.
EPS history for Valbiotis SA from 2015 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-0.57 -12.89%
2024 $-0.66 0.52%
2023 $-0.65 -50.16%
2022 $-1.31 21.14%
2021 $-1.08 73.93%
2020 $-0.62 -52.69%
2019 $-1.31 -13.46%
2018 $-1.52 37.41%
2017 $-1.10 517.05%
2016 $-0.18 -99.73%
2015 $-65.94 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$4.36 -858.10%
DK
$17.01 -3,058.78%
US
$42.53 -7,497.81%
US
$9.62 -1,773.47%
BE
$23.88 -4,253.77%
NL